Thurston Springer Miller Herd & Titak Inc. Has $2.41 Million Stock Position in Cencora, Inc. (NYSE:COR)

Thurston Springer Miller Herd & Titak Inc. raised its holdings in Cencora, Inc. (NYSE:COR) by 22.9% in the 1st quarter, HoldingsChannel reports. The fund owned 8,661 shares of the company’s stock after acquiring an additional 1,613 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Cencora were worth $2,408,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Whittier Trust Co. increased its position in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after buying an additional 44 shares during the period. Shepherd Financial Partners LLC increased its position in shares of Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock worth $1,223,000 after buying an additional 46 shares during the period. WASHINGTON TRUST Co increased its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares during the period. JFS Wealth Advisors LLC increased its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after buying an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. increased its position in shares of Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock worth $1,003,000 after buying an additional 47 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares of the company’s stock, valued at $89,027,442.53. This trade represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,253 shares of company stock valued at $11,102,417. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Down 0.9%

Cencora stock opened at $289.02 on Thursday. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm has a market capitalization of $56.02 billion, a price-to-earnings ratio of 41.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The firm’s fifty day moving average price is $285.86 and its two-hundred day moving average price is $259.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period last year, the firm earned $3.80 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date was Friday, May 16th. Cencora’s dividend payout ratio (DPR) is 25.52%.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent analyst reports. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Citigroup increased their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Wells Fargo & Company upgraded shares of Cencora from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $274.00 to $337.00 in a report on Tuesday. Finally, UBS Group raised their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.